Answers are grounded in this paper and cite their sources.
### Learning objectives Extracorporeal membrane oxygenation (ECMO) is an advanced form of temporary life support, to aid respiratory and/or cardiac function. It has been used since the early 1970s and is based on cardiopulmonary bypass technology and diverts venous blood through an extracorporeal circuit and returns it to the body after gas exchange through a semi-permeable membrane. ECMO can be used for oxygenation, carbon dioxide removal and haemodynamic support. Additional components allow thermoregulation and haemofiltration. The two most common forms of ECMO are veno-venous (VV) and veno-arterial (VA). In VV-ECMO, used to support gas exchange, oxygenated blood is returned to a central vein. In VA-ECMO, used in cases of cardiac or cardiorespiratory failure, oxygenated blood is returned to the systemic arterial circulation, bypassing both the heart and lungs. ### History The first adult survivor of ECMO was reported in 1972 in a patient who developed respiratory failure following a trauma.1 This was followed in 1976 with report of successful outcomes in moribund infants.2 The first randomised controlled trial (RCT) of VV-ECMO was performed in 1979 in 90 adult patients with respiratory failure and reported a high mortality rate and ECMO-associated complications.3 Today, this outcome is attributed to the old ECMO technology used and poor ventilatory management of patients. This trial diminished significantly the initial enthusiasm for ECMO in adult patients even if good outcomes continued to be observed when ECMO was used in young patients.4 In 1989, a group of enthusiast clinicians formed the Extracorporeal Life Support Organization (ELSO) and established a voluntary registry to …
No takes yet. Share an insight, caveat, or question.
Ali et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: